Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

CTNM Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $14.46M (cash outflow) fell 9.6% year over year, behind the +17.3% change in trailing-twelve-month net income. Sequentially, it fell 4.6% from the prior quarter. Over 3 fiscal years it compounded at +35.2% a year.

Context

  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$49.45M (-17.6%) for the fiscal year ending Dec 2026, a slowdown from the +41.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.46M-4.6% QoQ
Last fiscal yearDec 2025
-$59.98M+41.9% YoY
LTMMar 2026
-$58.44M+17.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.6%+4.8%+14.4 pp
1 year+41.9%-17.6%-59.5 pp
3-year CAGR+35.2%-2.2%-37.4 pp
5-year CAGR+3.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(59.98M) USD
Year-over-year change
-41.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CTNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.3% is the 6th highest of 7, against a peer median of +34.3%.
  • Over three fiscal years its annual growth of +35.2% compares with a peer median of +29.0%.
CTNM Competitors
Net Income for CTNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$222.39M USD-13.8%+21.9%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$199.48M USD+146.3%+75.1%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.28M USD+34.6%+118.7%536.4%
ANROAlto Neuroscience, Inc.LTM Mar 2026$74.31M USD+17.6%+31.7%—
ACIUAC Immune S.A.LTM Dec 2025CHF 70.34M CHF+38.1%-1.7%1968.6%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$58.44M USD+17.3%+35.2%—
GHRSGH Research PLCLTM Mar 2026$56.41M USD+34.0%+29.0%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$39.17M USD—+20.7%—
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding CTNM) —+34.3%+29.0%1252.5%

Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29M)(24.25M)22.72M(42.26M)(59.98M)
Depreciation & Amortization325K329K195K258K323K
Deferred Income Tax00000
Stock-Based Compensation1.75M1.93M2.22M6.8M10.04M
Change in Working Capital108K(1.27M)(1.02M)5.33M(6.04M)
Accounts Receivables00000
Inventory00000
Accounts Payables(110K)(230K)01.14M(869K)
Other Working Capital218K(1.04M)(1.02M)4.19M(5.17M)
Other Non-Cash Items553K3.14M(4.76M)(2.98M)344K
Operating Cash Flow(26.27M)(20.12M)19.35M(32.85M)(55.31M)
Capital Expenditures(168K)(118K)(414K)(514K)(231K)
Acquisitions (Net)00020K0
Purchases of Investments(66.78M)(64.7M)(141.87M)(226.41M)(162.5M)
Sales of Investments1.98M87.12M76.71M157.16M159.02M
Other Investing Activities00000
Investing Cash Flow(64.97M)22.3M(65.57M)(69.74M)(3.71M)
Debt Repayment0(1.25M)(3.75M)00
Common Stock Issued000108.21M112.69M
Common Stock Repurchased0(4K)(28K)00
Dividends Paid00000
Other Financing Activities113K15K(184K)790K0
Financing Cash Flow79.84M(1.24M)56.18M109M112.69M
Effect of Forex Changes00000
Net Change in Cash(11.4M)939K9.96M6.42M53.66M
Free Cash Flow(26.43M)(20.24M)18.94M(33.36M)(55.54M)

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Intrinsic Alpha fair value

Locked

Current Price

$9.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.